153 related articles for article (PubMed ID: 33757661)
1. Optimal oncologic and perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy are attainable at a community center.
Rog CJ; Lucas G; Reiter S; Vetto S; Alassas M; Ong ES
Am J Surg; 2021 Jun; 221(6):1200-1202. PubMed ID: 33757661
[TBL] [Abstract][Full Text] [Related]
2. Short-term outcomes in older patients with peritoneal malignancy treated with cytoreductive surgery and HIPEC: Experience with 245 patients from a national centre.
Keyes AM; Kelly ME; McInerney N; Khan MF; Bolger JC; McCormack E; Grundy J; McCormack O; MacHale J; Conneely J; Brennan D; Cahill R; Shields C; Moran B; Mulsow J
Eur J Surg Oncol; 2021 Sep; 47(9):2358-2362. PubMed ID: 33895028
[TBL] [Abstract][Full Text] [Related]
3. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Birgisson H; Enblad M; Artursson S; Ghanipour L; Cashin P; Graf W
Eur J Surg Oncol; 2020 Dec; 46(12):2283-2291. PubMed ID: 32873455
[TBL] [Abstract][Full Text] [Related]
4. Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways.
Eng OS; Blakely AM; Lafaro KJ; Fournier KF; Fackche NT; Johnston FM; Dineen S; Powers B; Hendrix R; Lambert LA; Ronnekleiv-Kelly S; Walle KV; Grotz TE; Leiting JL; Patel SH; Dhar VK; Baumgartner JM; Lowy AM; Clarke CN; Mogal H; Zaidi MY; Staley CA; Kimbrough C; Cloyd JM; Lee B; Raoof M
J Surg Oncol; 2020 Oct; 122(5):980-985. PubMed ID: 32627199
[TBL] [Abstract][Full Text] [Related]
5. Is there a role of repeat cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with relapse from peritoneal metastatic disease? A survival analysis.
Spiliotis J; Prodromidou A; Ferfelis M; Iavazzo C; Tsiatas M; Vaxevanidou A; Metaxas T
J BUON; 2020; 25(5):2504-2509. PubMed ID: 33277875
[TBL] [Abstract][Full Text] [Related]
6. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations - Part I: Preoperative and intraoperative management.
Hübner M; Kusamura S; Villeneuve L; Al-Niaimi A; Alyami M; Balonov K; Bell J; Bristow R; Guiral DC; Fagotti A; Falcão LFR; Glehen O; Lambert L; Mack L; Muenster T; Piso P; Pocard M; Rau B; Sgarbura O; Somashekhar SP; Wadhwa A; Altman A; Fawcett W; Veerapong J; Nelson G
Eur J Surg Oncol; 2020 Dec; 46(12):2292-2310. PubMed ID: 32873454
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS®) Society Recommendations - Part II: Postoperative management and special considerations.
Hübner M; Kusamura S; Villeneuve L; Al-Niaimi A; Alyami M; Balonov K; Bell J; Bristow R; Guiral DC; Fagotti A; Falcão LFR; Glehen O; Lambert L; Mack L; Muenster T; Piso P; Pocard M; Rau B; Sgarbura O; Somashekhar SP; Wadhwa A; Altman A; Fawcett W; Veerapong J; Nelson G
Eur J Surg Oncol; 2020 Dec; 46(12):2311-2323. PubMed ID: 32826114
[TBL] [Abstract][Full Text] [Related]
8. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
[TBL] [Abstract][Full Text] [Related]
9. Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience.
Nikiforchin A; Gushchin V; King MC; Baron E; Nieroda C; Sittig M; Sardi A
J Surg Oncol; 2021 Mar; 123(4):1030-1044. PubMed ID: 33524164
[TBL] [Abstract][Full Text] [Related]
10. Surgical and oncologic outcomes of hyperthermic intraperitoneal chemotherapy for uterine leiomyosarcoma: A systematic review of literature.
Matsuzaki S; Matsuzaki S; Chang EJ; Yasukawa M; Roman LD; Matsuo K
Gynecol Oncol; 2021 Apr; 161(1):70-77. PubMed ID: 33419612
[TBL] [Abstract][Full Text] [Related]
11. The Safety of Iterative Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis: A High Volume Center Prospectively Maintained Database Analysis.
Bekhor E; Carr J; Hofstedt M; Sullivan B; Solomon D; Leigh N; Bolton N; Golas B; Sarpel U; Labow D; Magge D
Ann Surg Oncol; 2020 May; 27(5):1448-1455. PubMed ID: 31873928
[TBL] [Abstract][Full Text] [Related]
12. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for perforated low-grade appendiceal mucinous neoplasms.
Abudeeb H; Selvasekar CR; O'Dwyer ST; Chakrabarty B; Malcolmson L; Renehan AG; Wilson MS; Aziz O
Surg Endosc; 2020 Dec; 34(12):5516-5521. PubMed ID: 31993814
[TBL] [Abstract][Full Text] [Related]
13. Outcomes following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies: 10 Year experience.
Graham I; Boston A; Hayward R; Berri R
Am J Surg; 2024 Apr; 230():78-81. PubMed ID: 38369417
[TBL] [Abstract][Full Text] [Related]
14. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy by laparoscopy via a single-port approach for low-grade peritoneal malignancy.
Dumont F; Duchalais E; Aumont A; Thibaudeau E
Surg Endosc; 2020 Jun; 34(6):2789-2795. PubMed ID: 32166549
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
[TBL] [Abstract][Full Text] [Related]
17. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
[TBL] [Abstract][Full Text] [Related]
18. Improved Survival with Experience: A 10-Year Learning Curve in Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery.
Leigh NL; Solomon D; Feingold D; Magge DR; Golas BJ; Sarpel U; Labow DM
Ann Surg Oncol; 2020 Jan; 27(1):222-231. PubMed ID: 31222683
[TBL] [Abstract][Full Text] [Related]
19. Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies?
Leigh N; Solomon D; Pletcher E; Labow DM; Magge DR; Sarpel U; Golas BJ
World J Surg Oncol; 2020 Jun; 18(1):124. PubMed ID: 32527272
[TBL] [Abstract][Full Text] [Related]
20. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
